News

Gladstone in the News March 18, 2026

Scientists Create Cancer-Fighting Immune Cells Right in the Body

UCSF News—Gladstone Affiliate Investigator Justin Eyquem and his collaborators at Gladstone and UCSF demonstrated a new method to engineer CAR T cells directly inside the body, opening the door to a future off-the-shelf cancer treatment without chemotherapy.

Gladstone Experts Cancer Genomic Immunology Eyquem Lab

Gladstone in the News November 4, 2025

Azalea Therapeutics Launches With $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient

Azalea Therapeutics—Gladstone Investigators Jennifer Doudna and Justin Eyquem founded a new company to advance next-generation genomic medicines.

Business Development Gladstone Experts Doudna Lab Eyquem Lab

Article June 18, 2024

Justin Eyquem Named a 2024 Pew-Stewart Scholar for Cancer Research

Eyquem, an affiliate investigator at Gladstone Institutes, is working to enhance the efficiency of CAR-T therapy, a cancer treatment that modifies T cells to target cancer cells.

Awards News Release Cancer Eyquem Lab

Gladstone in the News April 25, 2023

New Approach to CRISPR Delivery Opens the Door to Editing Multiple Genes Safely

Innovative Genomics Institute—Work from Alex Marson, director of the Gladstone-UCSF Institute of Genomic Immunology, and Affiliate Investigator Justin Eyquem demonstrates a new, more efficient and gentle method to introduce CRISPR editing machinery into cells.

Gladstone Experts Genomic Immunology Eyquem Lab Marson Lab CRISPR/Gene Editing

Article August 25, 2022

A Cellular Engineering Breakthrough: High-Yield CRISPR Without Viral Vectors

Scientists develop a new approach that produces enough cells for therapeutic applications

News Release Research (Publication) Genomic Immunology Esensten Lab Eyquem Lab Marson Lab CRISPR/Gene Editing